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SUMMARY
In vitro multiplication of rabies virus was inhibited by a condensed mineral ion, ammonium-5-tungsto-2-antimoniate (HPA 23). The inhibitory effect was evaluated by two different methods, plaque reduction and one step virus growth. Plaquing showed 50 % inhibition with 4"5/zg/ml of HPA 23 and complete inhibition with 12" 5/zg/ml. A reduction of two logs in virus yield was obtained in BHK21C~3S cells in suspension treated with 50/zg/ml of HPA 23. Inhibition also occurred when treatment with HPA 23 was started 18 to 24 h after infection in the plaque assay but no effect was seen when HPA 23 was added 48 h after virus inoculation. All these inhibitory effects of HPA 23 on rabies virus multiplication were observed at non cytotoxic doses. Therefore HPA 23 contrasts with other antiviral drugs which do not inhibit rabies virus multiplication without affecting the viability of cells.
Rabies virus is only poorly sensitive to antiviral drugs. In vitro activity of some antibiotics like actinomycin D and some nucleoside analogues have been reported (Harmon & Janis, I976; Flamand et aL I977) but inhibition of virus multiplication may be due to cellular toxicity rather than to a specific antiviral action. Ammonium-5-tungsto-2-antimoniate heteropolyanion (HPA 23) is a new antiviral compound which has shown significant activity in vitro against many RNA and DNA viruses at concentrations well below cellular toxic levels (Jasmin et al. I975; Werner et al. I976 ) . Furthermore, HPA 23 also had an in vivo protective effect in mice against infection initiated by RNA viruses, namely routine leukaemia and sarcoma viruses (Jasmin et aL I974, I975) , lymphocytic choriomeningitis virus (Streissle, I975) encephalomyocarditis virus and vesicular stomatitis virus (Werner et al. I976) . We report here on the specific in vitro inhibition of rabies virus multiplication by HPA 23 at non-cytotoxic doses.
The Flury high egg passage (HEP) strain of rabies virus was used for plaque assay and the Pasteur strain for the one-step growth experiments. The plaque assay described by Sedwick & Wiktor 0967) was used for titration of rabies virus. BHK~1C13S cells were suspended at Ioe/ml in complete MEM containing 2 % foetal calf serum and 0"3 % agarose and seeded on plastic Petri dishes (60× I5 mm) previously coated with 0.6% agarose solution. Virus dilutions were added in a vol. of o. I ml and the cultures incubated at 35 °C under 5 % CO2. After 6 days incubation, plaques were stained with a I/Io ooo neutral red solution in 0.6 % agarose and counted. The results are expressed as p.f.u./ml.
Experiments with a single cycle of virus multiplication were performed in BHK21C13S cells grown in suspension in complete MEM medium containing 1% foetal calf serum. The medium was removed on the following day by centrifugation, cells from the pellet were infected with approx. Io p.f.u./cell and incubated for 2 h at 37 °C. The cell concentration was adjusted to iot/ml in a medium containing 0"4 % BSA (Sigma) and incubated with stirring at 35 °C. Samples were harvested at different times and intra-cellular virus was titrated as described previously (Tsiang & Atanasiu, 197 ~) in vivo by intracerebral inoculation of mice and in vitro by the plaque assay method. 5-Tungsto-E-antimoniate was prepared according to the procedure previously described (Jasmin et al. I974) . Fresh solutions in culture medium were made for each experiment.
The effect of HPA 23 on rabies virus was assayed by incubating the latter with I mg/ ml of HPA 23 during 3o rain at 35 °C in MEM medium supplemented with 1% foetal calf serum. The residual infectivity was titrated by the plaque assay method. Only HPA z3 concentrations known to be non-toxic for BHK21C13S cells, and thus not inhibiting plaque formation, were used.
No cytotoxic effect of HPA 23 was observed when cells were maintained in agarose medium for 5 days at 35 °C and stained with neutral red if the medium contained Ioo/~g/ml or less of the compound. A 5o % reduction of cell survival was obtained with 8oo #g/ml. Thus it was assumed that the effect of HPA z 3 on plaque assay was specific. Addition of HPA 23 immediately after absorption of the virus resulted in a reduction of plaque number. The 5o% inhibitory dose was 4"5 #g/ml and a complete inhibition was obtained with I5 #g/ml (Fig. I) . When doses of Io #g/ml of HPA 23 were added to plates infected with dilutions of virus, plaque counts were significantly reduced (from 48-to 33o-fotds in different experiments). Timing of the action of HPA z3, determined by the plaque reduction, showed for both 5 and Io #g/ml a maximum inhibitory effect from I8 to 14 h. No protective effect was recorded 48 h after addition of HPA 23. Indeed, an enhancement of plaque numbers was observed in plates treated 72 h after inoculation. HPA 23 (5 to IO #g/ml) added 24 h before virus inoculation and remaining for the entire experiment has a complete inhibitory effectl Incubation of virus in presence of HPA 23 resulted in mean titres of Io4 .4 p.f.u./ml for HPA 23 treated particles and lO 5.o p.f.u, for untreated virus control.
Inhibition of virus production was assayed in one-step growth curves in cell suspensions. Only a partial inhibition occurred with 20 #g/ml of HPA 23, either measured by plaque titration or mouse inoculation (Fig. 2a) . With higher HPA 23 concentrations (50 #g/ml) a reduction of z logs in Virus yield was obtained with both titration methods (Fig. 2b) .
The data reported in this paper demonstrate a strong inhibitory effect of HPA 23 on fixed rabies virus growth in vitro. As shown with other viruses inhibited by HPA 23, this compound does not have a direct effect on the infectivity virus particles and it was active after the virus absorption period. In the plaque assay where plaque formation requires multiple cycles of virus replication, HPA 23 was active as late as 24 h after virus inoculation, a period which corresponds to a complete cycle of virus replication and probably to the initiation of infection of cells surrounding the initial focus of infection. Rabies virus is only poorly sensitive to antiviral drugs; it is insensitive to inhibitors of DNA synthesis like fluorodeoxyuridine and mitomycin (Hamparian, et al. I963) .
It has been reported that nucleoside analogue such as cytosine arabinoside, adenine arabinoside and 6-azauridine inhibit the replication of rabies virus in vitro (Harmon & Janis, I976) , but in these experiments a very low multiplicity of infection was used (3 x io -3 p.f.u./cell) and the virus in the control group was low 24 h after virus inoculation and did not attain maximal values until after 3 days of replication. As pointed out by the authors, considerable alterations in the morphology of the cells from the drug control monolayers were noticed. Similarly, it has been reported that high doses of actinomycin D and cytosine arabin0side inhibit rabies virus replicttion by affecting the host cell in such a way that it is no longer able to support normal virus production (Flamand, et al. I977) .
Therefore, HPA 23 represents a unique drug which inhibits rabies virus multiplication at HPA 23 has been shown to be a strong inhibitor of retrotranscriptase of murine tumour viruses (Chermann et al. I975 ) by acting at the binding site of the enzyme with the template primer. It is also active on cellular DNA polymerase (Ablashi et al. I977) . However, the mechanism of action of HPA 23 is not yet known and it is impossible to decide whether the
